<DOC>
	<DOC>NCT01238562</DOC>
	<brief_summary>This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics of a single-dose of YPEG-Filgrastim in cancer patients receiving chemotherapy, and will establish dose-response relationships between YPEG-Filgrastim and Filgrastim(rhG-CSF, TOPNEUTER).</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients</brief_title>
	<detailed_description />
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Age: 18～70yrs Signed informed consent Confirmed malignant tumor patients by histopathological or cytological diagnosis, suitable for chemotherapy with carboplatin combined with taxol or cyclophosphamide combined with pharmorubicin Karnofsky score ≥70 Life expectancy &gt;3 months WBC≥3,500 per cubic milliliter, ANC≥1,500 per cubic milliliter, PLT≥100,000 per cubic milliliter Normal coagulation function, no evidences of hemorrhage Normal liver, heart, kidney function Pregnant or lactating females Proven active infectious diseases (e.g. viral hepatitis, TB) Not adequately controlled infections Known hypersensitivity to filgrastim or any other components of the study drug Unstable or uncontrolled cardiac disease or hypertension Currently participated in any other clinical trials Patients with previous or expected to receive systemic radiotherapy Evidence of metastatic disease in bone marrow, brain, et al Alcoholic or drug abusers Other conditions which in the opinion of the investigator preclude enrollment into the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>cancer patient</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>carboplatin</keyword>
	<keyword>taxol</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>pharmorubicin</keyword>
</DOC>